CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 49 enrolled
Drug / intervention
Hyperpolarized 129XeMRIdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04512547
NCT04512547Phase 2Completed
CompareCT.gov

Oxidative Stress and Regional Airway Remodeling and Fibrosis in Obese Asthma

Bastiaan Driehuys·interventional·Posted Aug 13, 2020·Updated Mar 23, 2026

In Brief

A Phase 2 clinical trial evaluating Hyperpolarized 129XeMRI for Asthma and Obesity. Completed, enrolled 49 participants across 1 site.

Detailed Summary

40% of all asthma patients in the US are obese. Obese asthmatics have more severe disease than lean asthmatics and do not respond as well to conventional anti-inflammatory therapies. This proposal will utilize 3D functional imaging with 129XeMRI and single cell RNA sequencing to study mechanisms driving regional airway remodeling and fibrosis in obese asthma subjects and in preclinical models of obese asthma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma, Obesity
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedAug 13, 2020
Enrollment StartApr 1, 2021
Primary CompletionJan 31, 2025
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 5.9 years ago

Interventions

Hyperpolarized 129XeMRIdrug

Images obtained using 129XeMRI will be obtained on both obese asthmatic and non-asthmatics